Notice of meeting
... validly taken into account, confirmations have to be received by BNP Paribas Securities Services on the eve of the meeting at the latest, i.e. on May 9, 2017 at 3 p.m. (CET). ...
... validly taken into account, confirmations have to be received by BNP Paribas Securities Services on the eve of the meeting at the latest, i.e. on May 9, 2017 at 3 p.m. (CET). ...
united states securities and exchange commission - corporate
... commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discove ...
... commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discove ...
U.S. FDA Approves Number One U.S.-Prescribed Allergy Treatment Allegra for Over-The-Counter Use
... This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, stateme ...
... This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, stateme ...
Sanofi-Aventis Acquires Genzyme Corporation for $20 billion Brochure
... - On April 8, 2011, Sanofi-aventis completed the acquisition of Genzyme for about $20 billion in total, or $74 per share plus extra payments of up to $14 per share. The extra payments would depend on the achievement of commercial milestones of the leukemia drug Campath (alemtuzumab) in the multiple ...
... - On April 8, 2011, Sanofi-aventis completed the acquisition of Genzyme for about $20 billion in total, or $74 per share plus extra payments of up to $14 per share. The extra payments would depend on the achievement of commercial milestones of the leukemia drug Campath (alemtuzumab) in the multiple ...
REGENERON PHARMACEUTICALS INC (Form: 8
... Vietnam, Myanmar, and Sri Lanka. The excluded territory comprises the territory for a previously announced fasinumab collaboration between Regeneron and Mitsubishi Tanabe Pharma Corporation, which was entered into in September 2015. Under the Collaboration Agreement, Regeneron is eligible to receive ...
... Vietnam, Myanmar, and Sri Lanka. The excluded territory comprises the territory for a previously announced fasinumab collaboration between Regeneron and Mitsubishi Tanabe Pharma Corporation, which was entered into in September 2015. Under the Collaboration Agreement, Regeneron is eligible to receive ...
Modèles Industriels 2011 Æterna Zentaris est une entreprise de
... Alkermes founders were initially drawn together by their interest in using novel technology to address important, unmet medical needs. Today, the mission remains the same: we leverage sophisticated extended-release drug technologies to create therapies for widespread diseases such as central nervous ...
... Alkermes founders were initially drawn together by their interest in using novel technology to address important, unmet medical needs. Today, the mission remains the same: we leverage sophisticated extended-release drug technologies to create therapies for widespread diseases such as central nervous ...
World`s Leading Manufacturer, Seasonal Flu
... Pennsylvania, facility in the United States. In June 2013, the U.S. FDA approved the supplemental biologics license application (sBLA) for licensure of the new Sanofi Pasteur quadrivalent influenza vaccine (including four strains: two A strains and two B strains), Fluzone® Quadrivalent, for pediat ...
... Pennsylvania, facility in the United States. In June 2013, the U.S. FDA approved the supplemental biologics license application (sBLA) for licensure of the new Sanofi Pasteur quadrivalent influenza vaccine (including four strains: two A strains and two B strains), Fluzone® Quadrivalent, for pediat ...
Sanofi Pasteur Enters Agreement with Crucell for Next
... there is no treatment for rabies once symptoms of the disease have appeared. Post exposure prophylaxis for severe bites requires both active immunization, using vaccines such as those currently marketed by sanofi pasteur, and passive immunization in the form of rabies immunoglobulins (RIG). Rabies m ...
... there is no treatment for rabies once symptoms of the disease have appeared. Post exposure prophylaxis for severe bites requires both active immunization, using vaccines such as those currently marketed by sanofi pasteur, and passive immunization in the form of rabies immunoglobulins (RIG). Rabies m ...